Taiwan’s TFBS partners with Univercells Technologies for use of bioreactor to develop GMP processes
![](/46/pdcnewsitem/11/81/32/Univercells%20Technologies_scale-X%20carbo%20bioreactor.jpg)
Image: Univercells Technologies' scale-X™ carbo mid-scale fixed-bed bioreactor
TFBS will use Univercells’ scale-X™ carbo mid-scale fixed-bed bioreactor to support GMP viral vector operations
Taiwanese CDMO TFBS Bioscience has announced a partnership with Belgian biotech Univercells Technologies to leverage Univercells’ fixed-bed bioreactor for viral vector operations at its state-of-the-art facility in New Taipei City.
TFBS is Taiwan’s first viral vector contract development and manufacturing organisation (CDMO), which provides novel biomanufacturing technologies for flexible and scalable viral production. It plans to leverage Univercells’ scale-X™ carbo mid-scale fixed-bed bioreactor for good manufacturing practice (GMP) viral vector operations at its New Taipei City facility, which is undergoing an expansion.
The company is currently building out its QC testing and biological safety testing capabilities at the site and is set to begin construction of a new GMP-grade manufacturing facility for viral vectors soon.
Speaking about the partnership, TFBS CEO Thomas Yuan said: ‘The era of cell and gene therapy is moving rapidly here in APAC, and we are happy to add the scale-X carbo bioreactor to our toolbox of enabling technologies. The ability to support existing processes with simplified process transfer and scale-up from traditional flatware or packed-bed bioreactors, or to start with new process design is critical.’
He added that scale-X carbo bioreactor is ‘the only technology offering a mid-scale solution for GMP production, allowing customers to reach clinical stages with reduced time and costs, while achieving high productivity to keep programmes on track.’ The technology will be available from August 2022.
The full scale-X bioreactor portfolio includes the hydro for small-scale benchtop and research applications; carbo for process development, clinical and scalable commercial phases, which will be leveraged in this partnership; as well as the nitro for large-scale commercial production.
Mathias Garny, CEO of Univercells Technologies, added that the portfolio is ‘built on the tenets of intensification and integration, which will be critical to continuing to enable both internal and outsourced manufacturers as the market evolves.’
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance